| Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind … BG Appelberg, EK Syvalahti, TE Koskinen, OP Mehtonen, TT Muhonen, ... Journal of Clinical Psychiatry 62 (6), 448-452, 2001 | 213 | 2001 |
| Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes P Vehmanen, LS Friedman, H Eerola, M McClure, B Ward, L Sarantaus, ... Human molecular genetics 6 (13), 2309-2315, 1997 | 180 | 1997 |
| 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study IT Jantunen, TT Muhonen, VV Kataja, MK Flander, L Teerenhovi European Journal of Cancer 29 (12), 1669-1672, 1993 | 138 | 1993 |
| A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. S Pyrhönen, M Hahka-Kemppinen, T Muhonen Journal of clinical oncology 10 (12), 1919-1926, 1992 | 125 | 1992 |
| SME brand identity: its components, and performance effects T Muhonen, S Hirvonen, T Laukkanen Journal of Product & Brand Management 26 (1), 52-67, 2017 | 119 | 2017 |
| An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting IT Jantunen, VV Kataja, TT Muhonen European Journal of Cancer 33 (1), 66-74, 1997 | 102 | 1997 |
| Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression T Vlaykova, P Laurila, T Muhonen, M Hahka-Kemppinen, A Jekunen, ... Melanoma Research 9 (1), 59-68, 1999 | 95 | 1999 |
| Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma S Pyrhönen, M Hahka‐Kemppinen, T Muhonen, V Nikkanen, S Eskelin, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 93 | 2002 |
| A low proportion of BRCA2 mutations in Finnish breast cancer families. P Vehmanen, LS Friedman, H Eerola, L Sarantaus, S Pyrhönen, ... American journal of human genetics 60 (5), 1050, 1997 | 91 | 1997 |
| Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a … P Osterlund, T Salminen, LM Soveri, R Kallio, I Kellokumpu, ... The Lancet Regional Health–Europe 3, 2021 | 69 | 2021 |
| Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials M Hernberg, S Pyrhönen, T Muhonen Journal of Immunotherapy 22 (2), 145-154, 1999 | 67 | 1999 |
| Second cancer among long-term survivors from Hodgkin’s disease P Nyandoto, T Muhonen, H Joensuu International Journal of Radiation Oncology* Biology* Physics 42 (2), 373-378, 1998 | 67 | 1998 |
| The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. M Hernberg, T Muhonen, JP Turunen, M Hahka-Kemppinen, S Pyrhönen Journal of clinical oncology 14 (5), 1690-1696, 1996 | 63 | 1996 |
| Can the CD4+/CD8+ ratio predict the outcome of interferon-α therapy for renal cell carcinoma? M Hernberg, T Muhonen, S Pyrhönen Annals of oncology 8 (1), 71-77, 1997 | 59 | 1997 |
| Alport's syndrome in 78 patients: epidemiological and clinical study H Pajari, H Kääriäinen, T Muhonen, O Koskimies Acta Paediatrica 85 (11), 1300-1306, 1996 | 56 | 1996 |
| Effect of overall treatment time on local control in radical radiotherapy for squamous cell carcinoma of esophagus M Kajanti, R Kaleta, L Kankaanranta, T Muhonen, L Holsti International Journal of Radiation Oncology* Biology* Physics 32 (4), 1017-1023, 1995 | 54 | 1995 |
| Tenascin‐C in primary malignant melanoma of the skin S Ilmonen, T Jahkola, JP Turunen, T Muhonen, S Asko‐Seljavaara Histopathology 45 (4), 405-411, 2004 | 52 | 2004 |
| Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response T Vlaykova, L Talve, M Hahka-Kemppinen, M Hernberg, T Muhonen, ... Oncology 62 (3), 259-268, 2002 | 50 | 2002 |
| Prognostic value of tumour vascularity in primary melanoma AL Kariniemi, T Vlaykova, T Muhonen, S Pyrhönen, S Asko-Seljavaara Melanoma Research 9 (3), 273-278, 1999 | 47 | 1999 |
| Prognostic value of biomarkers in malignant melanoma M Hernberg, JP Turunen, K Von Boguslawsky, T Muhonen, S Pyrhönen Melanoma research 8 (3), 283-291, 1998 | 46 | 1998 |
